| Name | Title | Contact Details |
|---|
Conventional approaches aren't getting the job done so we've taken a whole new approach to helping individuals make more informed, confident choices. We've built a company for the sole purpose of engaging and delighting your employees and supporting them with every health benefits or healthcare question they have. We've proven that by giving employees and their families a great service and helping them get the right care that we can create more satisfied and committed employees and lower healthcare costs for employers. We've aligned our people, processes and technology to do the hard work of simplifying healthcare. We partner with large, innovative and forward-thinking organizations that share the belief that taking care of their employees when they need it most, is good for their business.
City of Gahanna, located in central ohio, offers family events, great parks and communities, plus the activities and businesses found at Creekside. Learn more about business development, emergency services, legislation, mayor’s court, city council, zon...
Preferred Health Strategies is a Rye, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Palmetto Health is South Carolina's largest and most comprehensive healthcare resource. In our progressive environment, the latest technology and treatment protocols go hand-in-hand with quality patient care.